With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse
has replaced transplant-related mortality as the primary cause of treatment failure for …

Abstract Venetoclax (VEN), a small-molecule inhibitor of B cell leukemia/lymphoma-2, is
now FDA approved (November 2018) for use in acute myeloid leukemia (AML), specific to …

Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in
treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to …

Venetoclax (VEN) is an FDA‐approved selective inhibitor of B‐cell leukaemia/lymphoma‐2
(BCL‐2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to …

Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation
(allo‐HCT) is often driven by immune‐related mechanisms and associated with poor …

Background Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in
elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in …

Simple Summary Venetoclax (VEN) is a potent oral inhibitor of the anti-apoptotic molecule
BCL2, approved for adults with chronic lymphocytic leukemia (CLL), and recently for naïve …

Relapsed and/or refractory (R/R) acute myeloid leukemia (AML) is hallmarked by dramatic
prognosis. Treatment remains challenging, with allogeneic hematopoietic stem cell …

The management of patients with acute myeloid leukemia (AML) relapsed post allogeneic
hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Intensive …

Background: Evidence that a venetoclax (VEN)-combined regimen is effective in
relapsed/refractory acute myeloid leukemia (R/R AML) is emerging. However, it is unknown …